Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Non-small-cell lung carcinoma | D002289 | — | — | 1 | 8 | 5 | — | — | 12 |
Lung neoplasms | D008175 | — | C34.90 | 1 | 5 | 5 | — | — | 9 |
Carcinoma | D002277 | — | C80.0 | 3 | 6 | 1 | — | — | 8 |
Melanoma | D008545 | — | — | 2 | 5 | 2 | — | — | 8 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | — | C80 | 7 | 2 | — | — | — | 7 |
Squamous cell carcinoma | D002294 | — | — | 2 | 4 | — | — | — | 5 |
Prostatic neoplasms | D011471 | — | C61 | 4 | 2 | — | — | — | 4 |
Renal cell carcinoma | D002292 | EFO_0000376 | — | 3 | 3 | — | — | — | 3 |
Basal cell carcinoma | D002280 | — | — | — | 3 | — | — | — | 3 |
Basal cell neoplasms | D018295 | — | — | — | 3 | — | — | — | 3 |
Uterine cervical neoplasms | D002583 | — | — | — | 1 | — | — | — | 1 |
Disease progression | D018450 | — | — | — | 1 | — | — | — | 1 |
Lymphoma | D008223 | — | C85.9 | — | 1 | — | — | — | 1 |
Hodgkin disease | D006689 | — | C81 | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Recurrence | D012008 | — | — | 1 | — | — | — | — | 1 |
Squamous cell neoplasms | D018307 | — | — | 1 | — | — | — | — | 1 |
Drug common name | Gilvetmab |
INN | gilvetmab |
Description | Gilvetmab is an antibody pharmaceutical. It is currently being investigated in clinical studies. |
Classification | Antibody |
Drug class | monoclonal antibodies |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | — |
PDB | — |
CAS-ID | — |
RxCUI | — |
ChEMBL ID | CHEMBL3990007 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | — |
UNII ID | 949NG8376D (ChemIDplus, GSRS) |